NWRN — Newron Pharmaceuticals SpA Share News
0.000.00%
Last trade - 00:00- CH₣174.16m
- CH₣182.76m
- €19.13m
Brief: Newron Pharmaceuticals says FDA approves Xadago for Parkinson's disease patients
Brief: Newron Pharmaceuticals FY net loss shrinks to EUR 15.2 mln
Europe Research Roundup: GlaxoSmithKline, Prudential, Nordea
Swiss stocks - Factors to watch on Jan 11
Brief: Newron: Seqirus and Zambon enter into a partnership for parkinson's disease product in Australia and New Zealand
Swiss stocks - Factors to watch on Jan 4
Brief: Newron Pharmaceuticals says encouraging preliminary results of Phase IIA study with Evenamide
Brief: Newron announces encouraging preliminary results of its phase IIa study with Evenamide in patients with schizophrenia
Swiss stocks - Factors to watch on Dec 26
Brief: Newron: FDA considers re-submitted NDA for Xadago to be complete class 2 response to complete response letter
Swiss stocks - Factors to watch on Oct 7
Brief: Newron Pharmaceuticals raises CHF 26.1 mln in a private placement of new shares
Brief: Newron Pharmaceuticals launches private placement of new shares
Swiss stocks - Factors to watch on Sept 22
Brief: Newron Pharmaceuticals re-submits US NDA for Xadago
Brief: Newron Pharmaceuticals H1 net loss widens to EUR 8.8 mln
Newron stock jumps on hopes for Xadago drug
Brief: Newron to re-submit US NDA for Xadago
Brief: Newron Pharmaceuticals announced initiation of STARS study